| 5-HT | 5-hydroxytryptamine or serotonin |
| ADAMPA | Alzheimer’s diseaseα-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid |
| ASIB | acute suicidal ideation and behavior |
| BDNF | brain-derived neurotrophic factor |
| EEG | electroencephalogram |
| FDA | Food and Drug Administration |
| GABA | gamma amino butyric acid |
| GABAAR | GABAA receptor |
| ICSS | intracranial self-stimulation |
| LPS | lipopolysaccharide |
| M-5MPEP | 2-(2-(3-methoxyphenyl)ethynyl)-5-methylpyridine |
| mGlu | metabotropic glutamate |
| mPFC | medial prefrontal cortex |
| mTOR | mammalian target of rapamycin |
| MS | multiple sclerosis |
| NMDA | N-methyl-D-aspartate |
| PBA | pseudobulbar affect |
| PCP | phencyclidine |
| PFC | prefrontal cortex |
| REM | rapid eye movement sleep |
| nREM | non-rapid eye movement sleep |
| PD | Parkinson’s disease |
| PTSD | post-traumatic stress syndrome |
| SOC | standard of care |
| SUD | substance abuse disorder |
| TRD | treatment-resistant depression |